Financial Performance - Reviva reported a net loss of approximately 0.90 per share, for the fiscal year ended December 31, 2024, a decrease from a net loss of approximately 1.65 per share, for the fiscal year ended December 31, 2023[6] - Cash and cash equivalents totaled approximately 23.4 million as of December 31, 2023[6] - The company reported a total operating expense of 39.5 million in 2023[15] - The company completed a public follow-on offering with aggregate gross proceeds of approximately $18.0 million in December 2024[7] Clinical Trials and Efficacy - The ongoing Phase 3 RECOVER study showed a dose-dependent efficacy with decreases in PANSS total scores of -15.2, -18.6, and -20.8 points at the 15, 30, and 50 mg doses respectively, from baseline to end-of-treatment at 52 weeks[3] - The pooled data from the RECOVER study demonstrated a clinically meaningful and sustained long-term efficacy for schizophrenia, with a PANSS total score decrease of 18.6 points (from 71.6 to 53), p ≤ 0.0001[3] - The anticipated registrational Phase 3 RECOVER-2 trial for brilaroxazine is expected to initiate in mid-2025, subject to additional financing[7] - A potential New Drug Application (NDA) submission for brilaroxazine is targeted for the fourth quarter of 2026[7] - The company expects to report the full data set from the RECOVER OLE study, including vocal and blood biomarker data, in the second quarter of 2025[2] Adverse Events - The most common treatment-related adverse events (TRAEs) reported were weight increase (3.2%), insomnia (1.8%), and somnolence (1.6%)[7]
Reviva Pharmaceuticals (RVPH) - 2024 Q4 - Annual Results